Helen Swaisland - Concepedia

Author

Helen Swaisland

Also Known As

H Swaisland, H. C. Swaisland, H. Swaisland, H.C Swaisland, H.C. Swaisland, Helen C Swaisland, Helen C. Swaisland, Helen Swaisland

Publications

7.9K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)Institute of Cancer Research AstraZeneca (Singapore)The Christie NHS Foundation Trust University of Manchester

About

Helen Swaisland is an author at AstraZeneca (United Kingdom) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	23	1.6K
2	Biochemistry	3	3	217
3	Health Sciences	2	2	141
4	Gastroenterology	1	1	70
5	Hepatology	1	1	28

Helen Swaisland

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers Peter C.C. Fong, David S. Boss, Timothy A. Yap, New England Journal of Medicine	2009	3.6K
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types José Baselga, Danny Rischin, Malcolm Ranson, Journal of Clinical Oncology	2002	829
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial Malcolm Ranson, Lisa A. Hammond, D. K. Ferry, Journal of Clinical Oncology	2002	762
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial Roy S. Herbst, Anne‐Marie Maddox, Mace L. Rothenberg, Journal of Clinical Oncology	2002	577
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors Kazuhiko Nakagawa, Tomohiro Tamura, Shunichi Negoro, Annals of Oncology Japanese PatientsOncologyMalignant DiseaseMedicinePathology	2003	274
Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and Metoprolol Helen Swaisland, Malcolm Ranson, Robert P. Smith, Clinical Pharmacokinetics Drug InteractionsPharmaceutical SciencePharmacokinetic Drug InteractionsPharmacological StudyMedicine	2005	155
Single-Dose Clinical Pharmacokinetic Studies of Gefitinib Helen Swaisland, Robert P. Smith, Alison Laight, Clinical Pharmacokinetics MedicinePharmacotherapyPharmacologyPhysiologically-based Pharmacokinetic ModelingPharmacokinetics	2005	141
Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man D. McKillop, Michael G. Hutchison, E. A. Partridge, Xenobiotica PathologyPharmacotherapyAlpha-1 Acid GlycoproteinOxidative StressGastrointestinal Peptide Hormone	2004	130
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib Joaquı́n Mateo, Víctor Moreno, Avinash Gupta, Targeted Oncology Parp Inhibitor OlaparibPharmacological StudyMedicineTablet FormulationPharmacotherapy	2016	126
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours Emma Dean, Mark R. Middleton, Thinn Pwint, British Journal of Cancer	2012	124

Page 1